Background: Dopa-responsive dystonia (DRD) and tetrahydrobiopterin (BH 4 ) defects are inherited disorders characterized by monoamine neurotransmitter deficiency with decreased activity of one of the BH 4 -metabolizing enzymes. The aim of the study was to determine the utility of cultured skin fibroblasts for the diagnosis of these diseases. Methods: Neopterin and biopterin production and GTP cyclohydrolase I (GTPCH) activity were measured in cytokine-stimulated fibroblasts; 6-pyruvoyltetrahydropterin synthase (PTPS), sepiapterin reductase (SR), and dihydropteridine reductase (DHPR) activities were measured in unstimulated fibroblasts. We examined 8 patients with DRD, 3 with autosomal recessive GTPCH deficiency, 7 with PTPS deficiency, 3 with DHPR deficiency, and 49 controls (35 fibroblast and 14 amniocyte samples). Results: Fibroblasts from patients with DRD and autosomal recessive GTPCH deficiency showed reduced GTPCH activity (15.4% and 30.7% of normal activity, respectively) compared with controls (P <0.001). Neopterin production was very low and biopterin production was reduced in both disorders. PTPS-and DHPR-deficient cells showed no enzyme activities; in PTPS deficiency the pattern of pterin production was typical (neopterin, 334 -734 pmol/mg; controls, 18 -98 pmol/mg; biopterin, 0 pmol/mg; controls, 154 -303 pmol/mg). Reference values of all enzyme activities and pterin production were measured in fibroblasts and also in amniocytes for prenatal diagnosis. Conclusions: Cultured skin fibroblasts are a useful tool in the diagnosis of BH 4 deficiencies. Intracellular neopterin and biopterin concentrations and GTPCH activity
widely distributed in animal tissues and constitutively expressed in fibroblasts (4 ) .
Autosomal recessive mutations in the genes coding for GTPCH, PTPS, or DHPR are responsible for BH 4 deficiencies (5) (6) (7) . Most of these deficiencies are characterized by neonatal hyperphenylalaninemia, developmental delay, progressive neurological deterioration, hypokinesia, hypersalivation and drooling, swallowing difficulties, truncal hypotonia, increased limb tone, myoclonus, and temperature instability, with onset in the first months of life (8 ) . More than 400 patients are tabulated in the international database (7 ) . Dopa-responsive dystonia (DRD) is a clinical syndrome characterized by childhood-onset dystonia (usually before 12 years of age), with dramatic clinical normalization that is sustained with low doses of l-Dopa (9 ) . The dystonia typically affects the legs, causing gait disturbance and postural instability. Signs and symptoms usually are progressive and worsen later in the evening or after exertion (diurnal fluctuation) (10 ) . Elements of Parkinsonism (rigidity, bradikynesia, and rest tremor) commonly occur, especially in adulthood (11 ) . Early motor development usually is normal, and hyperphenylalaninemia is absent. Recent studies have demonstrated that DRD is caused by autosomal dominant mutations in the coding region of the GCH1 gene, which encodes for GTPCH (12 ) , but only in 40 -50% of cases (13 ) . Reduced penetrance and gender-related vulnerability are reported, with females being more affected than males (2.5:1) (14 ) . The clinical phenotypic expression is quite diverse (15 ) , and many cases appear to be sporadic (16 ) .
Today, the diagnosis of BH 4 deficiencies is based on neonatal screening for phenylketonuria and urinary pterin analysis (17 ) . DRD is diagnosed mainly by clinical signs and symptoms and by response to l-Dopa/Carbidopa treatment. The examination of pterins and neurotransmitter metabolites in cerebrospinal fluid (CSF) requires an invasive procedure, but it is the only way to make a reliable diagnosis of DRD (10, 18 ) . Definitive diagnosis of BH 4 deficiencies is achieved by enzyme activity determinations and DNA analysis (8 ) .
PTPS and DHPR activities can be measured in liver biopsies (19, 20 ) , erythrocytes (21, 22 ) , and fibroblasts (23, 24 ) , whereas GTPCH is measurable in liver biopsies (25 ) . In mononuclear blood cells, GTPCH can be induced by phytohemagglutinin (26 ) , and reference values have been reported recently by Hibiya et al. (27 ) . However, this test is quite complex and must be performed within 20 h after sample collection (27 ) . In previous studies, fibroblasts were used for indirect measurement of pterin metabolism (28 ) , based on the induction of GTPCH expression with cytokines, but no data are available about nonpathological and pathological values. The possibility of measuring GTPCH activity in cytokine-stimulated fibroblasts was shown by Werner et al. (29 ) . In the present study, we used a similar stimulation procedure for measurement of both pterins and GTPCH activity. To our knowledge, fibroblasts have not been systematically tested for the other BH 4 -metabolizing enzymes. Cultured skin fibroblasts are easily used and practical for the diagnosis of many metabolic disorders. The samples can be transported at room temperature and stored for long periods after early passages for later analysis.
The aim of the present study was to demonstrate the utility of cultured skin fibroblasts as a diagnostic tool for DRD and BH 4 deficiencies. Particularly for DRD, the enzyme activity measurement is essential for final diagnosis. BH 4 metabolism was studied in fibroblasts from a large number of controls and in patients with different forms of BH 4 deficiency.
Materials and Methods subjects
Primary skin fibroblasts were obtained from 21 patients and 35 controls. Eight patients (four males, four females), 10 -45 years of age at the time of the skin biopsy, were affected by DRD (McKusick 128230). Thirteen patients, 2 months to 11 years of age at the time of the skin biopsy, were affected by BH 4 deficiencies. Of these, three patients (two males, one female) had an autosomal recessive GTPCH deficiency (McKusick 233910), seven (five males, two females) had a PTPS deficiency (McKusick 261640), and three (all males) had a DHPR deficiency (McKusick 261630). The diagnosis was confirmed by mutation analysis in all patients.
Control value biopsies were obtained from 17 subjects (10 males, 7 females) between birth and 1 year of age and 18 subjects (11 males, 7 females) between 1 and 45 years of age. No neurological abnormalities were detected in any of the controls. To establish reference values for prenatal diagnosis, 14 amniocyte samples collected between 15 and GFRP, GTP cyclohydrolase I feedback regulatory protein; PCD, pterin-4␣-carbinolamine dehydratase; PAH, phenylalanine-3-hydroxylase; TH, tyrosine-4-hydroxylase; TPH, tryptophan-5-hydroxylase; 5-OH-Trp, 5-hydroxytryptophan; NO, nitric oxide; NOS, nitric oxide synthase; AADC, aromatic amino acid decarboxylase; HVA, homovanillic acid; 5-HIAA, 5-hydroxyindoleacetic acid.
18 weeks of gestational age were also studied. The activities of all of the BH 4 -metabolizing enzymes, as well as neopterin and biopterin production after stimulation with cytokines, were measured in all samples.
The procedures used were in accordance with the current revision of the Helsinki Declaration of 1975.
materials
Sephadex G-50 Nick spin columns were from Pharmacia. DMEM, AmnioMax C-100 medium, trypsin/EDTA solution, antibiotics, and fetal calf serum were purchased from Life Technologies. GTP lithium salt, recombinant human IFN-␥, and TNF-␣ were from Sigma. Calf intestine alkaline phosphatase, NADH, NADPH, DHPR, peroxidase, leupeptin, and pepstatin were from Roche. Falcon cell culture plasticware was from Becton-Dickinson. ␥-Globulin and the protein assay dye reagent were from Bio-Rad. Ultrafree-MC filters with PL10 membrane were from Millipore.
Pteridine derivatives (6,7-dimethyltetrahydropterin and sepiapterin) were from Schircks Laboratories. Dihydroneopterin triphosphate was prepared enzymatically as described previously (30 ) , but using recombinant GTPCH (Thö ny B, Blau N. Enzymatic reactor for synthesis of dihydroneopterin triphosphate. Manuscript in preparation). Recombinant SR was purified in our laboratory (Thö ny B, unpublished work). All other chemicals were from Fluka.
cell culture and treatment with cytokines
Fibroblasts were cultured in DMEM containing 100 mL/L fetal bovine serum, 50 kilounits/L penicillin, and 50 mg/L streptomycin. Amniocytes were cultured in AmnioMax C-100 medium. Cells were passaged by trypsinization and studied at low passage numbers (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . All cells were Mycoplasma negative, as checked by the Hoechst staining method (31 ) . Cultures were kept at 37°C in humidified air containing 5% CO 2 .
To induce the expression of GTPCH, confluent cell monolayers in 78-cm 2 plates were stimulated with recombinant human IFN-␥ and TNF-␣ at concentrations of 250 and 100 kilounits/L, respectively, in fresh medium. After incubation for 24 h, cells were harvested by trypsinization, washed with phosphate-buffered saline, and immediately lysed for neopterin and biopterin measurement and for GTPCH activity assay. PTPS, DHPR, and SR are constitutively expressed in fibroblasts; therefore, their activities were tested in unstimulated cells. Confluent cells in 78-cm 2 plates were harvested, washed with phosphate-buffered saline, and kept at Ϫ80°C until analyzed for PTPS, DHPR and SR.
measurement of neopterin and biopterin production in cell extracts 
gtpch assay
The assay was performed as described previously by Hatakeyama and Yoneyama (33 ) , with some modifications. The assay monitors the conversion of the substrate GTP under saturating conditions to neopterin triphosphate, which is detected as neopterin, the oxidized and dephosphorylated product (Fig. 1 ).
Fibroblasts were analyzed immediately after 24-h incubation with cytokines. Cells from one confluent 78-cm 
ptps assay
The PTPS activity was measured in extracts from unstimulated cells. The assay was modified according to Shintaku et al. (21 ) . The unstable intermediate metabolite formed from dihydroneopterin triphosphate is converted to BH 4 by SR in the presence of NADPH. DHPR activity is necessary to stabilize the formation of BH 4 . BH 4 is then measured as the oxidized product, biopterin.
Unstimulated cells from one confluent 78-cm 2 plate were suspended in 150 L of lysis buffer (10 mmol/L Tris-HCl, pH 7.4, containing 10 mL/L Triton X-100) and lysed by freezing and thawing six times. After centrifugation at 15 000g for 5 min, 50 L of the supernatant was added to 60 L of reaction mixture containing 100 mmol/L Tris-HCl, pH 7.4, 10 mmol/L MgCl 2 , 1 mmol/L NADPH, 1 mmol/L NADH, 3 mU of SR, 220 mU of DHPR, and 60 mol/L dihydroneopterin triphosphate in a final volume of 110 L. A 50-L aliquot was incubated for 120 min at 37°C; another 50 L was used as a blank. A blank without cell extract, containing 50 L of lysis buffer and 60 L of reaction mixture, was incubated in the same run. The reaction was stopped by cooling the samples on ice and adding 15 L of 300 g/L trichloroacetic acid for protein precipitation, followed by centrifugation (5 min at 15 000g) and oxidation. Oxidation was performed by incubation of 50 L of the supernatant with 10 L of 10 g/L iodine for 60 min at room temperature in the dark. The same procedure was used for the blanks. After oxidation, 15 L of 10 g/L ascorbic acid was added to destroy excess iodine. Samples were diluted (1:4 by volume) with water and heated at 60°C for 2 h before being deproteinized through an Ultrafree-MC filter and analyzed by HPLC (32 ) . One unit of PTPS produces 1 mol of biopterin per minute at 37°C.
sr assay
The activity was assayed according to the method described by Ferre and Naylor (34 ) with some modifications. The assay monitors the conversion of sepiapterin to BH 2 , which is then measured as the oxidized product, biopterin.
Unstimulated cells from one confluent 78-cm 2 plate were suspended in 1 mL of lysis buffer (0.1 mol/L potassium phosphate buffer, pH 6. The sample was then deproteinized through an Ultrafree-MC filter and analyzed by HPLC (32 ) . One unit of enzyme activity produces 1 mol of biopterin per minute at 37°C.
dhpr assay
The activity of this enzyme was assayed, as described previously (24 ) , by monitoring the oxidation of NADH during the reduction of 6,7-dimethyldihydropterin (quinonoid isomer) to 6,7-dimethyltetrahydropterin, catalyzed by DHPR. The pterin derivative 6,7-dimethyltetrahydropterin was oxidized in situ by peroxidase in the presence of H 2 O 2 to q-6,7-dimethyldihydropterin and thus was recycled for the DHPR reaction.
Unstimulated fibroblasts from three confluent 78-cm 
statistical analysis
Normal values of neopterin, biopterin, and enzyme activities for controls were expressed as 5th, 50th, and 95th percentiles (Table 1) . Medians and minimum and maximum concentrations of the same analytes were used for pathological values because of the limited number of samples (Table 2 ). Statistical differences between multiple groups (neopterin and biopterin concentrations in controls and patients with different disorders; GTPCH activity in controls and patients with DRD and GTPCH defi-ciency) were tested using a one-way ANOVA with pairwise comparison according to Tukey. The unpaired Student t-test was used to compare results between two main control groups (amniocytes vs fibroblasts, males vs females, fibroblasts 0 -1 year vs fibroblasts Ͼ1 year) and between particular enzyme activities in controls and patients with different disorders. Differences were considered significant when P values were Ͻ0.05.
Results reference values for neopterin and biopterin production and gtpch activity in stimulated cells
After stimulation for 24 h with cytokines, the concentrations of neopterin and biopterin in amniocytes were significantly lower (P Ͻ0.001) than in skin fibroblasts collected after birth (Table 1 ). No differences in the production of neopterin (males, 30 -94 pmol/mg; females, 17-99 pmol/mg) and biopterin (males, 189 -301 pmol/ mg; females, 153-327 pmol/mg) were found between fibroblasts from males (n ϭ 21) and females (n ϭ 14). GTPCH activity was very low in amniocytes but increased in fibroblasts collected after birth (P Ͻ0.01). Fibroblast GTPCH activity was higher in females than in males (females, 1.4 -7.3 U/mg; males, 1.4 -3.9 U/mg; P ϭ 0.016). No significant difference was observed at different ages (0 -1 year, 1.7-4.9 U/mg; Ͼ1 year, 1.3-7.3 U/mg; P ϭ 0.97; activity 0 -10 years vs activity Ͼ10 years, P ϭ 0.74).
reference values for ptps, sr, and dhpr activities in unstimulated cells PTPS activity was higher in amniocytes than in fibroblasts (P Ͻ0.001; Table 1 ). A decrease in enzyme activity was observed in cells collected after the first year of age (0 -1 year, 0.5-1.7 U/mg; Ͼ1 year, 0.4 -0.7 U/mg; P ϭ 0.014). No differences were observed in other age groups after 1 year. Enzyme activities in males (0.4 -1.0 U/mg) vs females (0.4 -1.8 U/mg) showed no significant differences. SR activity was similar in cells collected before and after birth, as well as in males and females (males, 96 -202 U/mg; females, 120 -155 U/mg) and also in different age groups. DHPR activity was also similar in amniocytes and fibroblasts, as well as in males and females (males, 5-7.8 mU/mg; females, 4.2-8.9 mU/mg). A decrease in activity was observed after 1 year of age (0 -1 year, 5.4 -8.9 mU/mg; Ͼ1 year, 4.2-7.0 mU/mg; P ϭ 0.03). No differences were observed in other age groups after 1 year. There were no significant increases in PTPS, SR, and DHPR activities after stimulation with cytokines (data not shown).
measurement of neopterin and biopterin production and enzyme activities in fibroblasts from patients
Neopterin and biopterin concentrations were significantly different between controls and patients (P Ͻ0.001; Table  2 ). Cytokine-stimulated GTPCH-deficient cells (autosomal recessive form, three cases) showed extremely low concentrations of neopterin and biopterin (Fig. 2) and a median enzyme activity of 0.8 U/mg of protein (30.7% of the 50th percentile for normal activity). Cells from DRD patients (eight cases) also showed reduced neopterin and biopterin concentrations compared with controls (Fig. 2) . In both diseases, GTPCH activity was lower than in controls (P Ͻ0.001). In DRD patients, the median enzyme activity was 0.4 U/mg of protein (15.4% of the 50th percentile for normal activity), ranging between 0.1 (3.8%) and 0.6 U/mg (23%). GTPCH activity in the autosomal recessive form was higher than in the autosomal dominant form (GTPCH deficiency vs DRD, P Ͻ0.01). PTPSdeficient cells (seven cases) contained extremely high concentrations of neopterin (median, 475 pmol/mg; range, 334 -734 pmol/mg), and no measurable biopterin (Fig. 2) after stimulation with cytokines for 24 h. Enzyme activity, measured in unstimulated cells, was always below the detection limit (Ͻ0.05 U/mg, 7% of 50th percentile for controls). DHPR-deficient cells (three cases) showed intracellular pterin concentrations within reference values after stimulation (for neopterin, median 49 pmol/mg; range 29 -81 pmol/mg; for biopterin, median, 179 pmol/mg; range, 99 -181 pmol/mg; Fig. 2) , with biopterin concentrations significantly lower than in controls (P Ͻ0.001). Enzyme activity was not detectable in unstimulated fibroblasts from the same patients (Ͻ0.3 mU/mg, 5% of 50th percentile for controls).
Discussion
Autosomal recessive BH 4 deficiencies are characterized by the presence of neonatal hyperphenylalaninemia with abnormal urinary pterin excretion. The differential diagnosis between phenylketonuria and BH 4 deficiencies is extremely important because BH 4 -deficient patients do not respond to low phenylalanine dietary treatment. However, they benefit from early substitution therapy with BH 4 and neurotransmitter precursors (l-Dopa and 5-hydroxytryptophan) (36, 37 ) . DRD is diagnosed mainly by the typical clinical signs and symptoms and by the responsiveness to therapy with l-Dopa/Carbidopa. Hyperphenylalaninemia usually is not present in these patients; however, the oral phenylalanine loading test is consistent with a partial deficiency of BH 4 in the liver. Plasma phenylalanine/tyrosine ratios increase significantly 4 -6 h after the challenge (38 ) . Unfortunately, false-positive results with this test are possible; in fact, heterozygous phenylketonuric subjects show the same abnormal phenylalanine/tyrosine profiles (39 ) , whereas a small number of genetically confirmed DRD subjects showed no abnormalities with this test (40 ) . A lumbar puncture for CSF examination is invasive but most informative for the diagnosis of both recessive BH 4 deficiencies (41 ) and DRD (10 ) . Low CSF concentrations of homovanillic acid and 5-hydroxyindoleacetic acid, metabolites of dopamine and serotonin, respectively, are found in all variants of BH 4 deficiencies. Furthermore, both neopterin and biopterin are very low in GTPCH deficiency, neopterin is high and biopterin low in PTPS deficiency, and biopterin concentrations are very high in DHPR deficiency (8, 41 ) . CSF examinations in DRD patients revealed low concentrations of homovanillic acid, indicating a lack of dopamine synthesis, and low neopterin and biopterin concentrations are consistent with a GTPCH deficiency (10 ) .
The final diagnosis of BH 4 deficiencies is achieved by enzyme activity determinations and, with some limitations, by detection of mutations. PTPS and DHPR activities are measurable in many different tissues and cells such as erythrocytes (21, 22 ) , fibroblasts (23, 24 ) , and liver (19, 20 ) . Dried blood spots are routinely used for DHPR deficiency screening among hyperphenylalaninemic newborns (22 ) . Measurement of GTPCH activity is rather difficult because this enzyme is not expressed in blood cells and fibroblasts. Blau et al. (26 ) described an assay in phytohemagglutinin-stimulated mononuclear blood cells that was used to measure reduced activity in heterozygous and homozygous GTPCH subjects, and subsequently in DRD patients (12 ) . The test must be performed with fresh blood samples, within 20 h after sample collection (27 ) . Bezin et al. (42 ) suggested that the stimulation of lymphoblasts could lead to incorrect determinations of the actual activity of GTPCH in DRD patients.
Because not all GTPCH-deficient DRD patients have GCH1 mutations in the coding region or in the splice sites, which are detectable by the current genomic DNA sequencing of GCH1 (43 ) , and because of the high occurrence of sporadic mutations in this gene (14 ) , DNA testing for the autosomal dominant DRD is not suitable for routine clinical practice. Suzuki et al. (44 ) reported that in 40% of DRD patients no mutation was found in the GCH1 gene but that some of them showed reduced GTPCH activity in phytohemagglutinin-stimulated mononuclear blood cells. Therefore, measurement of enzyme activity is extremely important for the diagnosis of DRD. Recent studies demonstrated that cytokine-stimulated fibroblasts may be used for investigating BH 4 pathway integrity (28 ) , by measuring intracellular neopterin and biopterin production patterns, and for GTPCH activity measurement (29 ) . Here, we adapted these methods to investigate in cytokine-stimulated fibroblasts both pterin production patterns and GTPCH activity, with a diagnostic purpose. We first determined the reference values of intracellular neopterin and biopterin in fibroblasts and amniocytes after stimulation with cytokines. Under these conditions, amniocytes appeared to produce rather low amounts of pterins, consistent with their low GTPCH activity (Table  1) . Therefore, these cells are not suitable for prenatal diagnosis of GTPCH deficiency. On the other hand, prenatal diagnosis of PTPS and DHPR deficiency should be possible because the activities of these two enzymes are well detectable in amniocytes (Table 1) .
We observed that cells collected in the first year of life showed higher PTPS and DHPR activities than cells collected at a later age. GTPCH activity was slightly but not significantly higher when cells were collected during the first year of life. Because Hibiya et al. (27 ) reported a higher GTPCH activity in mononuclear blood cells in the first 10 years of life, we compared fibroblasts of these two control groups and found no significant difference. Only GTPCH activity was different between males and females, with higher activities in females. In contrast, lower activities in females were reported by Ichinose et al. (12 ) , and no difference was found by Hibiya et al. (27 ) in mononuclear blood cells. The analysis of a larger collection of controls is probably needed to better define these differences in fibroblasts; however, this is not of diagnostic importance.
The study of pathological samples allowed us to define the utility of cultured skin fibroblasts in the diagnosis of BH 4 defects and DRD. Except for SR, for which no patients have as yet been reported, all the studied enzymes exhibited very low activities in patient samples compared with controls (Table 2) . Indeed, PTPS and DHPR activities in unstimulated fibroblasts from the corresponding patients were below the detection limit (Ͻ7% and Ͻ5% of the 50th percentile of normal activity, respectively). PTPS deficiency was characterized by a typical pattern of pterin production in stimulated fibroblasts, with high neopterin concentrations and no measurable biopterin. The same pattern was observed in urine and CSF (8 ) . DHPR-deficient patients showed normal intracellular neopterin concentrations after stimulation, whereas biopterin concentrations were lower than in controls. Milstien et al. (28 ) suggested that the possible pattern of pterin production in these cells could be characterized by increased neopterin because of the lack of feedback inhibition of GTPCH by BH 4 , and reduced biopterin because of the fast transport rates of the oxidized forms of pterins out of the cells. This hypothesis would explain the differences of pterin patterns between the cell extracts and the extracellular fluids (plasma, urine, CSF), where increased biopterin is characteristic of the disease (41 ) .
GTPCH activity was lower in stimulated fibroblasts from patients with the autosomal dominant form than in those from patients with the autosomal recessive form. Previous measurements in phytohemagglutinin-stimulated mononuclear blood cells showed a reduction of GTPCH activity in DRD patients to Ͻ20% (12 ) , which was comparable to our finding, and a reduction of activity to Ͻ3% in autosomal recessive GTPCH deficiency (26 ) , in contrast to our results in stimulated fibroblasts (Table 2) . A dominant-negative effect of the mutated subunit on the activity of the wild-type subunit in DRD was suggested by Hirano and Ueno (45 ) . Indeed, cotransfection experiments with two mutant GTPCH alleles, identified in DRD patients, demonstrated that mutant proteins inhibit the activity of the wild-type enzyme. In contrast, cotransfection of the mutant allele found in a patient with autosomal recessive GTPCH deficiency failed to inhibit the wild-type activity, producing much higher GTPCH activity (46 ) . The molecular mechanism of this dominant-negative effect and the different phenotype, which is more severe in recessive GTPCH deficiency despite higher enzyme activity in vitro, remain to be explained. Recently, Suzuki et al. (44 ) reported that a reduction in the amount of enzymatic protein could be responsible for the lower GTPCH activity in DRD compared with the autosomal recessive GTPCH deficiency. A dominant-negative effect might still be acting at an earlier stage, at either the translational or the transcriptional level. Regardless, GTPCH activity measurement in cytokine-stimulated fibroblasts was diagnostic for both disorders.
In conclusion, skin cultured fibroblast assays are confirmatory for all suspected BH 4 deficiencies. Our studies now provide for the first time reference values for direct and indirect (intracellular neopterin and biopterin) estimation of enzyme activity. The study of BH 4 metabolism is particularly useful in DRD patients because it allows an etiologic diagnosis when other tests are inconclusive.
